Studies performed overseas have found that there appears to be a link between taking the drug pioglitazone (which is found in Actos, ActoPlus Met, ActoPlus Met XR, and Duetact) for more than 12 months and developing cancerous tumors on the bladder. Did you take any of the previously mentioned medications under doctor’s orders and then later develop bladder cancer? If so, our attorneys can help ensure you get the financial compensation you are entitled to receive. Our attorneys:
- Fight on your behalf so that you can focus on recovery
- Ensure you are treated with respect and understanding
- Work hard to see your needs met & your case swiftly resolved
A recent FDA announcement concerning the safety of Actos, ActoPlus Met, ActoPlus Met XR, and Duetact, which all contain pioglitazone, has led to over 1,000 lawsuits being filed.
The lawsuits have arisen based on allegations that the manufacturer of these prescription drugs, Takeda Pharmaceutical, had knowledge of the bladder cancer risk in connection with pioglitazone and withheld the information from the public and health care professionals.
Studies performed overseas have since found that there appears to be a link between taking the drug pioglitazone for more than 12 months and developing cancerous tumors on the bladder.
That’s why if you have taken Actos, ActoPlus Met, ActoPlus Met XR, or Duetact for a period of at least 3 months and were subsequently diagnosed with bladder cancer you may be eligible for a lawsuit and monetary compensation.
To determine your eligibility you can contact our attorneys for a free, no obligation consultation where we will review the details of your case.
In 1999, the Food and Drug Administration (FDA) in the United States approved the use of pioglitazone (brand name Actos) for the treatment of Type II Diabetes Mellitus. This is an adult onset metabolic disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency.
The drug was sold for this purpose for many years, until scientific research came to light that linked the drug to the formation of bladder cancer.
A French study reported the bladder cancer link in June 2011, beginning the controversy that now surrounds Actos.
The study found that in addition to the increased risk of bladder cancer in all patients, those who took the drug for longer than 12 months had an even greater increased risk of developing bladder cancer.
Not long after the release of this study, both the French and German governments banned the sale and use of Actos and other medications containing the drug pioglitazone.Review My Case Now
Even with the scientific evidence cited above, the FDA has not banned Actos for use in the U.S., however on June 15, 2011 the FDA did release a safety announcement concerning the link between Actos and bladder cancer.
This safety announcement was released based on data from the initial 5 years of an ongoing 10 year study that showed a 40 percent increase in bladder cancer among patients who had taken Actos for longer than one year.
Based on this perceived link between bladder cancer and the drug pioglitazone, the FDA has recommended that pioglitazone should not be prescribed to anyone who already has bladder cancer, and should be used cautiously with patients who have a history of the disease.
In addition, the FDA cautioned health care professionals and Actos users to be on the alert for possible signs of bladder cancer, such as:
- Urine that contains blood
- Lower abdominal pain or lower back pain
- The need to urinate urgently
- Discomfort or pain during urination
Because of the possible link between bladder cancer and Actos, the FDA also announced that new warning labels and patient medication guides would be needed that reflect the risks associated with the use of Actos.
These new labels and patient medication guides were issued on August 4, 2011 by the FDA.
The new labels and guides recommend that pioglitazone not be prescribed to patients who currently have bladder cancer, and that caution should be used when prescribing pioglitazone to patients who have a history of bladder cancer.
The new drug labels specifically state that patients should inform their physician if they – "experience any sign of blood in the urine or a red color in the urine or other symptoms such as new or worsening urinary urgency or pain on urination since starting pioglitazone, as these may be due to bladder cancer."Review My Case Now
Currently, there is no class action Actos bladder cancer lawsuit.
Instead, each case is filed individually and is represented individually.
Based on the recent court history regarding pharmaceutical negligence it is unlikely that any class action lawsuit will be filed in the case of Actos bladder cancer.
There is an ongoing federal multi-district litigation panel that has been established in the Western District of Louisiana to consolidate the pre-trial proceedings of Actos bladder cancer lawsuits.
In addition, California, Illinois, and Missouri have consolidated Actos litigation within their state courts.Review My Case Now
Patients who have taken Actos, ActoPlus Met, ActoPlus Met XR, or Duetact for a period of at least 3 months and were subsequently diagnosed with bladder cancer may take legal steps if they or their physician was not properly warned about the risk of bladder cancer associated with the use of Actos by the manufacturer.
If this includes you, we recommend that you contact us immediately for a free evaluation.
We will determine, based on the individual details of your case, if you are eligible to file an Actos bladder cancer lawsuit.
Our experienced drug injury lawyers are prepared to take your case and seek justice for you in the courts.
Please note that there is a time limit for filing these Actos claims, so don't delay in contacting us